Kleo’s core technologies are modular in nature and can rapidly produce novel compounds by ‘mixing and matching’ different combinations of tumor cell binders and binders that engage the immune system.
Kleo is committed to expanding its transformative immuno-oncology platforms and progressing important novel therapies into clinical development.
Opportunities for research collaborations and licensing include the following:
- Binder discovery and molecule creation for targets of interest to partner
- Novel repurposing of partner’s binders and/or compounds to create new therapies
- Adding functionality to partner’s off-the-shelf therapeutic monoclonal antibodies
- Co-develop targets of interest to Kleo
Please contact us at BD@kleopharmaceuticals.com.
Peptidream, Inc. has entered into a multi-target research collaboration with Kleo to co-develop novel immune-oncology therapies in multiple indications. Utilizing Kleo’s proprietary ARMTM and SyAMTM platform technologies, along with Peptidream’s proprietary Peptide Discovery Platform System ("PDPS"), we are advancing a number of collaboration molecules in multiple indications. Our lead collaboration molecule is a CD38-ARM projected to enter clinical trials in multiple myeloma by the end of 2019.